Alba Brandes
Alba Brandes
Azienda USL-Irccs Bologna
Email verificata su ausl.bologna.it
TitoloCitata daAnno
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma
R Stupp, WP Mason, MJ Van Den Bent, M Weller, B Fisher, ...
New England Journal of Medicine 352 (10), 987-996, 2005
129552005
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the …
R Stupp, ME Hegi, WP Mason, MJ van den Bent, MJB Taphoorn, ...
The lancet oncology 10 (5), 459-466, 2009
44752009
Bevacizumab plus radiotherapy–temozolomide for newly diagnosed glioblastoma
OL Chinot, W Wick, W Mason, R Henriksson, F Saran, R Nishikawa, ...
New England Journal of Medicine 370 (8), 709-722, 2014
12702014
Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and …
MJ van den Bent, AF Carpentier, AA Brandes, M Sanson, MJB Taphoorn, ...
Journal of Clinical Oncology 24 (18), 2715-2722, 2006
7202006
Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951
MJ van den Bent, AA Brandes, MJB Taphoorn, JM Kros, ...
Journal of clinical oncology 31 (3), 344-350, 2012
7112012
MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients
AA Brandes, E Franceschi, A Tosoni, V Blatt, A Pession, G Tallini, ...
Journal of Clinical Oncology 26 (13), 2192-2197, 2008
6582008
European Organisation for Research and Treatment of Cancer Brain Tumour and Radiation Oncology Groups; National Cancer Institute of Canada Clinical Trials Group. Effects of …
R Stupp, ME Hegi, WP Mason, MJ van den Bent, MJ Taphoorn, ...
Lancet Oncol 10 (5), 459-466, 2009
5972009
MGMT promoter methylation in malignant gliomas: ready for personalized medicine?
M Weller, R Stupp, G Reifenberger, AA Brandes, MJ Van Den Bent, ...
Nature Reviews Neurology 6 (1), 39, 2010
5452010
Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial
RO Mirimanoff, T Gorlia, W Mason, MJ Van den Bent, RD Kortmann, ...
J Clin Oncol 24 (16), 2563-2569, 2006
4652006
Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034
MJ van den Bent, AA Brandes, R Rampling, MCM Kouwenhoven, JM Kros, ...
Journal of Clinical Oncology 27 (8), 1268, 2009
4562009
Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre …
R Stupp, ME Hegi, T Gorlia, SC Erridge, J Perry, YK Hong, KD Aldape, ...
The lancet oncology 15 (10), 1100-1108, 2014
4542014
Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE. 3
T Gorlia, MJ van den Bent, ME Hegi, RO Mirimanoff, M Weller, ...
The lancet oncology 9 (1), 29-38, 2008
4462008
High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial
AJM Ferreri, M Reni, M Foppoli, M Martelli, GA Pangalis, M Frezzato, ...
The Lancet 374 (9700), 1512-1520, 2009
4322009
IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of …
MJ Van den Bent, HJ Dubbink, Y Marie, AA Brandes, MJB Taphoorn, ...
Clinical Cancer Research 16 (5), 1597-1604, 2010
3852010
MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC Brain Tumor Group …
MJ van den Bent, HJ Dubbink, M Sanson, CR van der Lee-Haarloo, ...
Journal of Clinical Oncology 27 (35), 5881, 2009
2502009
Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma
M Weller, T Gorlia, JG Cairncross, MJ Van Den Bent, W Mason, ...
Neurology 77 (12), 1156-1164, 2011
2412011
Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO)
AA Brandes, A Tosoni, G Cavallo, R Bertorelle, V Gioia, E Franceschi, ...
British journal of cancer 95 (9), 1155, 2006
2402006
Disease progression or pseudoprogression after concomitant radiochemotherapy treatment: pitfalls in neurooncology
AA Brandes, A Tosoni, F Spagnolli, G Frezza, M Leonardi, F Calbucci, ...
Neuro-oncology 10 (3), 361-367, 2008
2182008
Recurrence pattern after temozolomide concomitant with and adjuvant to radiotherapy in newly diagnosed patients with glioblastoma: correlation with MGMT promoter methylation status
AA Brandes, A Tosoni, E Franceschi, G Sotti, G Frezza, P Amista, ...
J Clin Oncol 27 (8), 1275-1279, 2009
2172009
Epidemiology of glial and non-glial brain tumours in Europe
E Crocetti, A Trama, C Stiller, A Caldarella, R Soffietti, J Jaal, DC Weber, ...
European journal of cancer 48 (10), 1532-1542, 2012
2132012
Il sistema al momento non può eseguire l'operazione. Riprova più tardi.
Articoli 1–20